Table 6.
Antiviral activities of GRL‐98065 (11) against multidrug‐resistant clinical isolates.
|
Virus[a] |
EC50 [nm][b] |
|||||
|---|---|---|---|---|---|---|
|
SQV |
RTV |
NFV |
APV |
DRV |
11 (GRL‐98065) |
|
|
HIV‐1ERS104pre (wild‐type X4) |
8 |
25 |
15 |
29 |
3.8 |
0.5 |
|
HIV‐1MDR/TM (X4) |
180 (23) |
>1000 (>40) |
>1000 (>67) |
300 (10) |
4.3 (1) |
3.2 (6) |
|
HIV‐1MDR/MM (R5) |
140 (18) |
>1000 (>40) |
>1000 (>67) |
480 (17) |
16 (4) |
3.8 (8) |
|
HIV‐1MDR/JSL (R5) |
290 (36) |
>1000 (>40) |
>1000 (>67) |
430 (15) |
27 (7) |
6 (12) |
|
HIV‐1MDR/B (X4) |
270 (34) |
>1000 (>40) |
>1000 (>67) |
360 (12) |
40 (11) |
3.9 (8) |
|
HIV‐1MDR/C (X4) |
35 (4) |
>1000 (>40) |
420 (28) |
250 (9) |
9 (2) |
2.7 (5) |
|
HIV‐1MDR/G (X4) |
33 (4) |
>1000 (>40) |
370 (25) |
320 (11) |
7 (2) |
3.4 (7) |
[a] The amino acid substitutions identified in the protease‐encoding region compared to the consensus type B sequence cited from the Los Alamos database. See reference 113 for details. [b] Effective concentration by 50 %.